Aduro Biotech Inc

Aduro Biotech — Investor Presentation (January 2018)

35 slides from Aduro Biotech's investor presentation, Jan 8, 2018

  1. Slide 1: Corporate Presentation January 2018

    Corporate Presentation January 2018 P I O N E E R I N G I M M U N O T H E R A P Y . T R A N S F O R M I N G L I V E S . 1

  2. Slide 2: Disclaimer

    Disclaimer Special Note Regarding Forward Looking Statements This presentation and the accompanying oral presentation include express and implied forward looking statements regarding the current intentions, expectations, estimates, opinions and beliefs of Aduro Biotech, Inc. (“Aduro”) that are not h

  3. Slide 3: Aduro Highlights

    Aduro Highlights 3 distinct immunotherapy platforms Partnered & wholly owned assets 374m in cash at 3Q17 Operating capital through 2020 Comprehensive R&D pipeline Locations in Berkeley & Oss (US) (NL) 3

  4. Slide 4: Aduro's Development Pipeline

    Aduro’s Development Pipeline STING Pathway Activators ADU S100 ADU S100 áPD 1 ADU S100 Ipi STING Discovery Planned Using a tumor’s composition to Multiple tumors Multiple tumors STING Blok activate a patient specific Phase 1 Phase 1b Melanoma Autoimmune anti cancer response Phase 1 Adjuvant Infectio

  5. Slide 5: Notable 2017 Accomplishments

    Notable 2017 Accomplishments Corporate achievements and notable news Expanded Scientific Advisory Board with the appointment of several new key opinion leaders Received $2 million in development milestone payment from Merck Bolstered intellectual property position with three new STING patents Awarde

  6. Slide 6: STING

    STING 6

  7. Slide 7: STING: Off the Shelf Patient Specific Therapy

    STING: Off the Shelf Patient Specific Therapy Family of proprietary small molecules Synthetic compounds more potent than natural STING ligands Strong IP position ADU S100 – first in class lead oncology product candidate Activates all known human STING receptors ADU S100 demonstrated preclinical anti

  8. Slide 8: STING Pathway Activators and Inhibitors

    STING Pathway Activators and Inhibitors Breadth of Potential STING Pathway Opportunities STING Pathway Agonists & Antagonists Oncology Infectious Disease Autoimmunity / Inflammation $750M collaboration ($250M upfront) Development cost sharing WW; Profit Share 50% in US, 45% in EU 5 & Japan; Mid teen

  9. Slide 9: ADU S100: Activity in B16 Melanoma Tumor Model

    ADU S100: A Proprietary Highly Active Cyclic Dinucleotide Activity in B16 Melanoma Tumor Model Significantly Better than TLR Agonists ADU S100 More Efficacious than Naturally Occurring CDN ADU S100 More Efficacious Than TLR Agonists 3000 Groups: (N=8) 2500 Groups: (N=8) ] HBSS 3 2500 HBSS control ]

  10. Slide 10: ADU S100: Protective Immunity in Preclinical Model

    ADU S100: Protective Immunity in Preclinical Model Immunity in Lung Metastases Following IT Injection of Primary Tumor HBSS ADU S100 B16 Tumor Model Lung Metastases 50 P<0.001 Groups: (N=8) 40 HBSS control ADU S100 Nodules 30 Tumor 20 Lung 10 0 HBSS ADU S100 B16 subcutaneous injection in the flank (

  11. Slide 11: ADU S100: Synergistic Activity in Combination with Anti PD1

    ADU S100: Synergistic Activity in Combination with Anti PD1 ADU S100 Renders Anti PD 1 Resistant Tumors Sensitive to Checkpoint Therapy 4T1 mammary carcinoma model Distal Injected Tumor Tumor Low Dose HBSS áPD 1 ADU S100 áPD 1 2500 2000 ] ] 3 3 [mm 2000 [mm 1500 1500 1000 Volume 1000 HBSS IT Volume

  12. Slide 12: ADU S100 (MIW815): Phase I Monotherapy Ongoing

    ADU S100 (MIW815): Phase I Monotherapy Ongoing PHASE 1 MONOTHERAPY DOSE ESCALATION Patients: Cutaneously accessible, treatment refractory, advanced or metastatic solid tumors or lymphomas Primary Objective: Safety and tolerability Part 1: Dose Escalation ongoing ADU S100 Continue ADU S100 until prog

  13. Slide 13: Part 1: Monotherapy Dose Escalation Ongoing

    Part 1: Monotherapy Dose Escalation Ongoing MTD not reached No dose limiting toxicities observed Safety profile favorable for use in combination therapy Determining a dose that triggers optimal biologic activity Heterogenous population of heavily pre treated patients Includes patients who had previo

  14. Slide 14: ADU S100 (MIW815): Combination with PDR001 Ongoing

    ADU S100 (MIW815): Phase 1 Combination with PDR001 Ongoing PHASE 1b – PDR001 COMBINATION DOSE ESCALATION OF COMBINATION THERAPY Patients: Patients with advanced/metastatic solid tumors or lymphomas Primary Objective: Safety and tolerability N~175 Part 1: Dose Escalation ongoing ADU S100 áPD 1 (PDR00

  15. Slide 15: ADU S100 (MIW815): Combination with Ipilimumab Planned

    ADU S100 (MIW815): Combination with Ipilimumab Planned PHASE 1 – PLANNED IPILIMUMAB COMBINATION DOSE ESCALATION Part 1: Dose Escalation – planned in 2018 ADU S100 Ipi Patients: PD 1 relapsed or Continue ADU S100 until PD refractory melanoma Continue Ipi x 4 cycles Primary Objective: Safety and toler

  16. Slide 16: B select

    B select 16

  17. Slide 17: B select Monoclonal Antibodies

    B select Monoclonal Antibodies Proprietary ultra selective B cell panning method coupled with rigorous functional screening Earlier iteration of technology at Organon led to discovery of pembrolizumab Technology probes the entire B cell immune response to yield high affinity antibody candidates targ

  18. Slide 18: Anti APRIL: BION 1301 a First in Class Antagonist Antibody

    Anti APRIL: BION 1301 a First in Class Antagonist Antibody Blocking APRIL Inhibits Multiple Myeloma Tumor Growth, Drug Resistance & Immune Suppression in Preclinical Studies Anti APRIL Bone APRIL APRIL mAb Marrow Binds BCMA BCMA MM Cells Proliferation APRIL mAb of MM Cells blocks binding BCMA Multip

  19. Slide 19: Anti APRIL: Preclinical Data

    Anti APRIL: Compelling Preclinical Data Anti APRIL Displays Anti tumor Activity and Inhibits Regulatory T cells (novel mechanism driven through TACI) Single Agent Anti tumor Activity in vivo Human INA6 MM cells engrafted into fetal bone chips (NOD Scid mice) controlled by anti APRIL 500 Control 400

  20. Slide 20: Anti APRIL: BION 1301 Phase 1/2 Monotherapy Trial Ongoing

    Anti APRIL: BION 1301 Phase 1/2 Monotherapy Trial Ongoing Patient population: relapsed or refractory multiple myeloma whose disease has progressed after at least 3 prior systemic therapies PHASE 1 – Dose Escalation Primary Objective: Safety and establish recommended dose for expansion N: 3 per dosin

  21. Slide 21: Anti APRIL: Multiple Myeloma Incidence Increasing

    Anti APRIL: Multiple Myeloma Incidence Increasing Despite New Entrants, There are no Curative Options; All Patients Relapse and Become Refractory 160,000 140,000 120,000 100,000 80,000 Incidence 60,000 Prevalence 40,000 20,000 2015 2020 2024 2015 2020 2024 2015 2020 2024 US 5 EU Japan Source: Datamo

  22. Slide 22: Anti CTLA 4: ADU 1604 Humanized IgG1 Antibody

    Anti CTLA 4: ADU 1604 Humanized IgG1 Antibody ADU 1604 targets unique epitope; IND enabling work underway – Potent inhibitor of CTLA 4 in vitro and in vivo Strongly enhanced T cell responses Human (in vitro) T cell activation 4 0 A D U 1 6 0 4 1 0 D 1 h I g G 1 i s o t y p e c o n t r o l 3 0 ) l m

  23. Slide 23: Opportunity with Anti CTLA 4

    Opportunity with Anti CTLA 4 Phase 1 Study to Begin in 2018 Checkpoint inhibitors have been transformational therapies in diverse cancers Anti CTLA 4 MOA validated with demonstrated anti cancer activity Relatively rare development asset Established in melanoma; promising combo data in other tumor ty

  24. Slide 24: pLADD

    pLADD 24

  25. Slide 25: pLADD: Listeria based Delivery and Antigen presenting Platform

    pLADD: Listeria based Delivery and Antigen presenting Platform Designed to Stimulate Innate Immune Response (cytokines, chemokines, gamma delta T cells and NK cells) & Antigen specific Adaptive T cell Response (CD4 and CD8 T cells) Adaptive Immune Response Dendritic Neoantigen Tumor Specific Cell Ex

  26. Slide 26: pLADD: Personalized Neoantigen Immunotherapy

    pLADD: Personalized Neoantigen Immunotherapy Utilizing Patient Specific Tumor Antigens pLADD approach Technology well suited to maximize the potential of personalized therapy Allows for engineering of ~25 antigens Manufactured through small scale process Deletion of two virulence genes in bacterial

  27. Slide 27: pLADD: Phase 1 Proof of Concept Ongoing MSS Colorectal Cancer

    pLADD: Phase 1 Proof of Concept Ongoing MSS Colorectal Cancer Checkpoint inhibitor monotherapy has not been effective in this patient population Medium mutational burden; ~10 100 potential neoantigens pLADD well suited for MSS CRC: innate and adaptive anti tumor immunity Recruits NK cells to the liv

  28. Slide 28: Out licensed

    Out licensed 28

  29. Slide 29: Novel CD27 Agonist Licensed to Merck

    Novel CD27 Agonist Licensed to Merck Distinctly targets previously undiscovered functional epitope on CD27 Triggers CD27 in solution Leads to potent activation of the CD27 co stimulatory pathway In preclinical studies, anti CD27 agonist induced T cell mediated anti cancer response Complete tumor era

  30. Slide 30: ADU 214: Advanced by Janssen in Lung Cancer

    ADU 214: Advanced by Janssen in Lung Cancer ADU 214/JNJ 64041757 Expresses mesothelin and EGFR VIII Encouraging initial results in monotherapy Phase 1 study Patients with advanced (stage IIIb) or metastatic (stage IV) NSCLC 5/9 patients achieved stable disease Evidence of mesothelin specific T cell

  31. Slide 31: Business Overview

    Business Overview 31

  32. Slide 32: Portfolio of Wholly Owned & Partnered Assets

    Portfolio of Wholly Owned & Partnered Assets Aduro Programs Program Collaboration Indication Terms Commercial $700M (upfront & potential milestones); Aduro leads US sales; ADU S100 & Others Oncology $50M equity; Co development & co Profit/expense share U.S., major EU commercialization and Japan; Roy

  33. Slide 33: 3Q17 Financials and Patent Position

    3Q17 Financials and Patent Position Strong Financial Position Cash & cash equivalents as of $373.5 M 9/30/2017 Operating expenses for $33.1 M third quarter 2017 Shares outstanding as of 77.3 M 10/25/2017 Extensive Patent Portfolio Global Rights (inclusive of in licensed patents) 100 issued compositi

  34. Slide 34: Upcoming Milestones

    Upcoming Milestones H1 H2 2018 2018 Anti CD27 Merck Milestone Payment Clinical progress Anti CTLA 4 Submit filing to initiate clinical evaluation ADU S100 Ipilimumab Multiple tumors Initiate dose escalation ADU S100 monotherapy Multiple tumors Complete dose escalation portion of Phase 1 study ADU S1

  35. Slide 35: aye

    O o =) eC) <x aye Oo Lu jie © a

Aduro Biotech — Investor Presentation (January 2018) on 6ix